Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | DAO | P14920 | 1/20 | 0.74 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.74 |
| ▸ | CES2 | O00748 | 5/20 | 0.61 |
| ▸ | CES1 | P23141 | 5/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL28919560 | 1.00 | TSHR (0.74) | TSHRDAONAPRTCES2CES1 | |
| Terephthalic Acid SCHEMBL29395194 | 0.95 | TSHR (0.65) | TSHRDAONAPRTCES2CES1 | |
| Terephthalic Acid SCHEMBL9341320 | 0.95 | TSHR (0.65) | TSHRDAONAPRTCES2CES1 | |
| Terephthalic Acid SCHEMBL28554228 | 0.95 | TSHR (0.65) | TSHRDAONAPRTCES2CES1 | |
| Terephthalic Acid SCHEMBL27877780 | 0.88 | ALDH1A1 (0.77) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL28096536 | 0.86 | NAPRT (0.61) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL9664197 | 0.86 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL5731290 | 0.86 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL10457491 | 0.86 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL11154585 | 0.86 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518898-B2 | Cytoprotective composition comprising hesperidin or pharmaceutically acceptable salt thereof as an active ingredient | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2013-08-27 | — | — | US | disclosed |
| CN-101010267-B | Optimized Liquid Phase Oxidation | GRUPO PETROTEMEX SA DE CV | 2013-05-29 | — | — | CN | disclosed |
| CN-101410173-B | Oxidation system with internal secondary reactor | EASTMAN CHEM CO | 2013-03-06 | — | — | CN | disclosed |
| CN-102941041-A | Oxidation system with internal secondary reactor | EASTMAN CHEM CO | 2013-02-27 | — | — | CN | disclosed |
| WO-2009151173-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF VIRAL DISEASES CONTAINING RHODIOLA EXTRACTS, FRACTIONS, THE ISOLATED FLAVONOID COMPOUNDS THEREFROM, DERIVATIVES COMPOUNDS THEREOF OR THE PHARMACEUTICALLY ACCEPTABLE SALTS AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-17 | — | — | WO | disclosed |
| US-20090227526-A1 | CYTOPROTECTIVE COMPOSITION COMPRISING HESPERIDIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2009-09-10 | — | — | US | disclosed |
| WO-2009102083-A1 | NOVEL CLITOCYBIN DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION CONTAINING THE EXTRACT OF CLITOCYBE AURANTIACA KCTC 11143BP OR THE NOVEL CLITOCYBIN DERIVATIVES FOR PREVENTION OF AGING AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227526-A1 | CYTOPROTECTIVE COMPOSITION COMPRISING HESPERIDIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT | HES1, PHLPP1, PHLPP2 | TSHR 4409/4885DAO 4625/4885NAPRT 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.